Highlights
- Second quarter 2026 revenue rose 113% to $1,645 million, including $817 million from the acquired BD business.
- Legacy Waters revenue grew 7%, while the GAAP net loss was $136 million, or $1.39 per diluted share.
- Acquisition accounting added $154 million of fair value step-up expense and $244 million of intangibles amortization in the quarter.
- Total debt reached $5,086 million at July 4, 2026, after Waters issued $3.5 billion of senior notes in March.
Waters (NYSE:WAT) shares were trading near their 52-week high at USD 456.82 on October 21, 2026, up 3.16%. The laboratory instruments maker completed its combination with the BD Biosciences and Diagnostic Solutions business in February, issued $3.5 billion of senior notes in March, and reported second quarter 2026 results in a quarterly report filed August 11.
Based in Milford, Massachusetts, Waters is a Delaware corporation whose products are used by pharmaceutical, industrial, nutritional safety, environmental, academic and government customers. After the acquisition it reports three segments: Analytical & Materials Sciences, covering liquid chromatography, mass spectrometry, thermal analysis and rheometry instruments with precision chemistry consumables; Biosciences, which sells cell analysis instruments, software, reagents and single cell multiomics solutions; and Advanced Diagnostics, which supplies infectious disease testing systems and assays. Its fiscal year ends December 31.
Acquisition Lifts Revenue While GAAP Results Turn to a Loss
On February 9, 2026, Waters completed the acquisition of the Biosciences and Diagnostic Solutions business of Becton, Dickinson and Company in a Reverse Morris Trust, with total consideration valued at $13 billion. BD shareholders received 38.5 million Waters shares, and former Waters holders owned about 60.8% of the combined company. Results include the acquired business only from the closing date, which limits comparability with prior periods.
Revenue for the quarter ended July 4, 2026 was $1,645 million against $771 million a year earlier. The acquired business contributed $817 million; excluding it, legacy revenue rose 7%, helped by broad growth across product lines and regions, while currency reduced total growth by two points. Instrument systems revenue rose 47% to $455 million, consumables rose to $765 million from $165 million, and service revenue grew 43% to $425 million. Segment revenue was $756 million for Analytical & Materials Sciences, $368 million for Biosciences and $521 million for Advanced Diagnostics.
The GAAP operating loss was $86 million, compared with operating income of $188 million a year earlier. Drivers included $154 million of fair value step-up expense in cost of revenue, $244 million of purchased intangibles amortization, $39 million of transaction and integration costs and $49 million of severance. Interest expense, net, rose to $55 million from $10 million. The net loss was $136 million, or $1.39 per diluted share, versus net income of $147 million, or $2.47. Total segment operating income, which excludes certain items, was $511 million, a 31.1% margin.
Workforce Reduction, Debt and Cash Flow
In the second quarter, Waters cut about 3% of its employees, recording $49 million of severance costs. The company expects annual salary-related savings of about $120 million, with roughly $67 million expected in 2026.
Total debt was $5,086 million at July 4, 2026, against $1,407 million at year end, and cash and cash equivalents were $539 million, versus $588 million. The March 23 issuance of $3.5 billion of senior notes, with maturities from 2027 to 2036, repaid a $3.5 billion delayed-draw term loan assumed in the transaction. A $450 million spin-off term loan remains outstanding and matures in February 2028. The company said it was in compliance with its debt covenants and had $1.5 billion available under its revolving credit facility.
For the first half, operating cash flow was $198 million versus $301 million, a decline the company tied to a net $157 million receivable due from BD and $105 million of transaction and integration payments. Waters made no open market share repurchases in 2026 and has $1.0 billion of authorization remaining through January 21, 2028.
Outlook and Items to Watch
The quarterly report does not include numeric financial guidance. It notes that the acquisition makes period comparisons less meaningful and that the company may be eligible for refunds of tariffs previously paid after the Supreme Court's February 20 ruling on IEEPA tariffs; the amount and timing are uncertain. The company says tariffs, government funding changes and trade policy could affect results. These statements reflect the company's expectations, not predictions.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...